Imunon highlights 14.7-month overall survival gain in Phase 2 IMNN-001 ovarian cancer study as Phase 3 trial advances
Bitget2026/09/24 12:05- Imunon highlighted final Phase 2 results already presented, pointing to a survival benefit for IMNN-001 in newly diagnosed advanced ovarian cancer.
- The update framed the Phase 2 findings as supportive evidence for its ongoing Phase 3 OVATION 3 trial, where survival is the primary endpoint.
- Management described the treatment as avoiding the systemic safety issues that derailed earlier IL-12 programs, supporting continued late-stage development.
- Enrollment in OVATION 3 is running ahead of plan, keeping the company’s targeted enrollment completion in the first quarter of 2029 intact.
- Imunon also cited early MRD study observations already shared, suggesting improved disease clearance signals, while noting the dataset remains too small for efficacy conclusions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
